Document:

EX-10.3

 EXHIBIT 10.3 

SCICLONE PHARMACEUTICALS, INC. 

EXECUTIVE SEVERANCE AGREEMENT 

This Executive Severance Agreement (the “Agreement”) is effective as of February 9, 2014, by and
between MENG Chun Cai (the “Executive”) and SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”). 

RECITALS 
 A. The Executive presently serves as
Vice President, Compliance and Legal Affairs of the Company, and performs significant strategic and management responsibilities necessary to the continued conduct of the Company’s business and operations. 

B. The Board of Directors of the Company (the “Board”) through
its Compensation Committee has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of the Executive of the Company. 

C. The Board believes that it is imperative to provide the Executive with certain severance benefits upon the Executive’s termination of
employment without Cause that will provide the Executive with enhanced financial security and provide sufficient incentive and encouragement to the Executive to remain with the Company. 

AGREEMENT 
 The Executive and the Company agree
as set forth below: 
 1. Terms of Employment. The Company and the Executive agree that the Executive’s employment is based on
the original offer letter and labor contract terms and that their employment relationship may be terminated by either party at any time, with or without Cause, and, if applicable, in accordance with Section 2 below. If the Company terminates
Executive’s employment without Cause, the Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided by this Agreement. During his employment with the Company, the Executive agrees to
devote his full business time, energy and skill to his duties with the Company. These duties shall include, but not be limited to, any duties consistent with the Executive’s position that may be assigned to the Executive from time to time by
the Company or the Board. 
 2. Severance Benefits Upon Termination without Cause. Subject to the limitations set forth in
Sections 3 and 4 below, if the Executive’s employment with the Company is terminated without Cause, then the Executive shall be entitled to receive, in addition to the compensation and benefits earned by the Executive through the date of
his or his termination, severance benefits as follows: 
 (a) The Executive shall be entitled to receive severance pay in the form of
continuation of Employee’s base salary and allowances (at the time of entering into this agreement an annual amount of RMB 2,300,000) in effect on Employee’s termination date for 

  
 1 

 
twelve (12) months following such termination date. These payments will be made on the Company’s ordinary payroll dates starting with the first pay date after the termination date, and
will be subject to standard payroll deductions and withholdings. 
 (b) The Executive shall be entitled to receive a separation bonus equal
to the gross amount of fifty percent (50%) of the average annual performance bonus paid to the Executive for the two (2) most recent fiscal years for which bonuses have been paid prior to the termination date. 

(c) The Company shall, if permitted under the Company’s existing health insurance plans, continue the Executive’s existing group
health insurance coverage. If not so permitted, the Company shall reimburse the Executive for any health insurance premiums paid by the Executive for continued group health insurance coverage. Such health insurance coverage or reimbursement of
premiums shall continue until the earlier of (i) twelve (12) months after the date of the Executive’s Involuntary Termination or (ii) the date on which the Executive commences New Employment. 

(d) Disability; Death. If the Company terminates the Executive’s employment as a result of the Executive’s Disability, or
death, then the Executive shall not be entitled to receive any severance pay or benefits under this Agreement. 
 3. Release of Claims;
Resignation. The Executive’s entitlement to any severance pay or benefits under Section 2 is conditioned upon the Executive’s execution and delivery to the Company of (a) a general release of known and unknown claims in the
form attached hereto as Exhibit A and (b) a resignation from all of the Executive’s positions with the Company, including from the Board and any committees thereof on which the Executive serves, in a form satisfactory to the
Company. 
 4. Consulting Services. During the six (6) months following any termination without Cause for which the Executive
receives the severance pay and benefits described in Section 2, the Executive shall be retained by the Company as an independent contractor to provide consulting services to the Company at its request for up to eight (8) hours per week.
These services shall include any reasonable requests for information or assistance by the Company, including, but not limited to, the transition of the Executive’s duties. Such services shall be provided at mutually convenient times. For the
actual provision of such services, the Company shall pay to the Executive a consulting fee of $1,000 on a full eight hour day basis, pro-rated for the number of hours of service, plus reasonable out-of-pocket expenses (for example, travel and
lodging). 
 5. Definition of Terms. The following terms referred to in this Agreement shall have the following meanings: 

(a) “Cause” shall mean any of the following: 

(i) the Executive’s theft, dishonesty, misconduct or falsification of any records of the Company, its successor, or any subsidiary of
the Company or its successor (collectively, the “Company Group”); 

  
 2 

 (ii) the Executive’s misappropriation or improper disclosure of confidential or proprietary
information of the Company Group; 
 (iii) any intentional action by the Executive which has a material detrimental effect on the
reputation or business of the Company Group; 
 (iv) the Executive’s failure or inability to perform any reasonable assigned duties
after written notice from the Company Group of, and a reasonable opportunity to cure, such failure or inability; 
 (v) any material breach
by the Executive of any employment agreement between the Executive and the Company Group, which breach is not cured pursuant to the terms of such agreement; or 

(vi) the Executive’s conviction of any criminal act which impairs the Executive’s ability to perform his or hisduties for the
Company Group. 
 (b) “Disability” means the inability of the Executive, in the opinion of a qualified physician, to
perform the essential functions of the Executive’s position with the Company Group, with or without reasonable accommodation, because of the sickness or injury of the Executive. 

(c) “New Employment” shall mean any employment obtained by the Executive after the termination of the Executive’s
employment with the Company. 
 6. Nonsolicitation. During his or his employment with the Company, and for a period of one
(1) year following the termination of his or his employment for any reason, the Executive shall not directly or indirectly recruit, solicit, or induce any person who on the date hereof is, or who subsequently becomes, an executive, sales
representative or consultant of the Company, to terminate his or his relationship with the Company. 
 7. Successors. 

(a) Company’s Successors. Any successor to the Company or to all or substantially all of the Company’s business and/or assets
shall be bound by this Agreement in the same manner and to the same extent as the Company. For all purposes under this Agreement, the term “Company” shall include any successor to the Company’s business and/or assets. 

(b) Executive’s Successors. All rights of the Executive hereunder shall inure to the benefit of, and be enforceable by, the
Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. The Executive shall have no right to assign any of his or his obligations or duties under this Agreement to any
other person or entity. 

  
 3 

 8. Notice. 

(a) General. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been
duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. In the case of the Executive, mailed notices shall be addressed to the Executive at the home address which he
most recently communicated to the Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary. 

(b) Notice of Termination. Any termination by the Company Group or the Executive of their employment relationship shall be communicated
by a written notice of termination to the other party. 
 9. Miscellaneous Provisions. 

(a) No Duty to Mitigate. The Executive shall not be required to mitigate the amount of any payment contemplated by this Agreement
(whether by seeking New Employment or in any other manner), nor shall any such payment be reduced by any earnings that the Executive may receive from any other source. 

(b) Waiver. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is
agreed to in writing and signed by the Executive and by an authorized officer of the Company (other than the Executive). No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other
party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time. 
 (c)
Choice of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California. 

(d) Severability. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or
enforceability of any other provision hereof, which shall remain in full force and effect. 
 (e) Arbitration. Any dispute,
controversy or claim arising out of or relating to this contract, including the validity, invalidity, breach or termination thereof, shall be settled by arbitration in Hong Kong under the Hong Kong International Arbitration Centre Administered
Arbitration Rules in force with the Notice of Arbitration is submitted in accordance with these rules . Judgment upon any decision or award rendered by the arbitrator may be entered in any court having jurisdiction over the matter. The Executive and
the Company knowingly and willingly waive their respective rights to have any such disputes or claims tried to a judge or jury. 
 (f)
Prior Agreements; Controlling Agreement in the Case of a Change in Control. This Agreement supersedes all prior understandings and agreements, whether written or oral, regarding the subject matter of this Agreement, provided, however, that
the Change in Control Agreement dated February 9, 2014 (the “CIC Agreement”) between Executive and 

  
 4 

 
Company shall remain in place and is not amended or waived in any way hereby. If Executive is entitled to receive severance benefits under the CIC Agreement, then the CIC Agreement shall be
controlling. 
 [Remainder of Page Left Intentionally Blank] 

  
 5 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company
by its duly authorized officer, as of the day and year first above written. 
  

			
	SCICLONE PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Friedhelm Blobel

		 	FRIEDHELM BLOBEL

  

	
	EXECUTIVE
	
	 /s/ Chun Cai Meng

	MENG Chun Cai

  
 6 

 Exhibit A 

RELEASE 
 In exchange for
the severance pay and benefits described in the Executive Severance Agreement between SciClone Pharmaceuticals, Inc. (the “Company”) and me of February 9, 2014, I hereby release the Company, its parents and subsidiaries,
and their officers, directors, employees, attorneys, stockholders, successors, assigns and affiliates, of and from any and all claims, liabilities, and causes of action of every kind and nature, whether known or unknown, based upon or arising out of
any agreements, events, acts, omissions or conduct at any time prior to and including the execution date of this Release, including, but not limited to: all claims concerning my employment with the Company or the termination of that employment; all
claims pursuant to any PRC Labor Contract Law and the regulations promulgated by the local government having jurisdiction over the employment. 

I am knowingly, willingly and voluntarily releasing any claims I may have under relevant local laws. I acknowledge that the consideration
given for the release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. 
 I hereby
waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any unknown claims I may have, and I affirm that it is my intention to release all known and unknown
claims that I have or may have against the parties released above. 

  
 1 

 This Release contains the entire agreement between the Company and me regarding the subjects
above, and it cannot be modified except by a document signed by me and an authorized representative of the Company. 
  

									
		 		 		 	EXECUTIVE
				
	Date:	 	  
	 		 	  

		 		 		 	MENG Chun Cai
				
		 		 		 	SCICLONE PHARMACEUTICALS, INC.
					
	Date:	 	  
	 		 	By:	 	  

					
		 		 		 	Its:	 	  

  
 2EX-10.1

 Exhibit 10.1 

FIRST AMENDMENT TO LEASE 

THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of this
21st day of February, 2014, by and between ARE-MA REGION NO. 23, LLC, a Delaware limited liability company (“Landlord”), and IDERA PHARMACEUTICALS, INC., a Delaware
corporation (“Tenant”). 
 RECITALS 

A. Landlord and Tenant are now parties to that certain Lease Agreement dated as of October 31, 2006 (the “Lease”).
Pursuant to the Lease, Tenant leases certain premises consisting of approximately 26,589 rentable square feet (the “Premises”) in a building located at 167 Sidney Street, Cambridge, Massachusetts. The Premises are more
particularly described in the Lease. Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease. 

B. The Base Term of the Lease is scheduled to expire on May 31, 2014. 

C. Landlord and Tenant desire, subject to the terms and conditions set forth below, to amend the Lease to, among other things, extend
the Base Term of the Lease through August 31, 2017 (“Extended Expiration Date”). 
 NOW, THEREFORE, in
consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, Landlord and Tenant hereby agree as follows: 
  

	 	1.	Base Term. The expiration of the Base Term of the Lease is hereby extended through the Extended Expiration Date. 

  

	 	2.	Base Rent. Tenant shall continue paying Base Rent as required under the Lease through August 31, 2014; provided that Base Rent for the months of June, July and August of 2014 shall be abated in full
so long as Tenant shall not be in Default under the terms of the Lease beyond any applicable notice and cure periods. 

Commencing on September 1, 2014, Base Rent shall be payable pursuant to the following schedule: 

 

			
	9/1/14 – 8/31/15:	  	$53.35 per rentable square foot of the Premises per annum
	9/1/15 – 8/31/16:	  	$54.42 per rentable square foot of the Premises per annum
	9/1/16 – 8/31/17:	  	$55.50 per rentable square foot of the Premises per annum

  

	 	3.	Services. At Tenant’s request, Landlord will engage DENS Facility Services or another property management company, in Landlord’s sole discretion, to (i) manage mechanical systems at the
Project, and (ii) provide landscaping and snowplowing services at the Project (collectively, the “Additional Services”). 

Tenant acknowledges and confirms that pursuant to Section 5 of the Lease, Tenant will be responsible for all costs, expenses and
obligations of every kind and nature whatsoever, incurred by Landlord in connection with the Additional Services, including without limitation, all third party charges attributable thereto, but Landlord shall not be entitled to 

  

			
		
	

	 	 Copyright © 2005, Alexandria Real Estate Equities, Inc. ALL

RIGHTS RESERVED. Confidential and Proprietary – Do Not

Copy or Distribute. Alexandria and the Alexandria Logo are

registered trademarks of Alexandria Real Estate Equities, Inc.

  

									
		 		 	1	 		 	

 an additional fee or override based on the foregoing. For information purposes only, the third
party costs attributable to the Additional Services for the first twelve months after the date this First Amendment is signed has been estimated at $16,000, but the actual third party costs may vary and such estimate shall not limit Tenant’s
liability for such third party costs. Notwithstanding the foregoing, during the 18 month period commencing on June 1, 2014 and ending on November 30, 2015, Tenant shall not be responsible for any costs associated with HVAC system serving
the Premises other than (i) costs that are considered preventative or annual maintenance expenses (as determined by Landlord in its sole discretion) and (ii) any damage to the HVAC system caused by Tenant’s negligence or willful
misconduct, which costs shall be the sole responsibility of Tenant. 
 Tenant acknowledges and confirms that Landlord is entitled under
Section 5 of the Lease to recover from Tenant “all costs, expenses and obligations of every kind and nature whatsoever relating to the Project,” including without limitation, a portion of Landlord’s payroll costs allocable to the
Project, as Landlord may determine in its good faith discretion from time to time during the Term. For information purposes only, the payroll costs attributable to the Project for the first twelve months after this First Amendment is signed has been
estimated at $5,000, but the actual payroll costs attributable to the Project may vary and such estimate shall not limit Tenant’s liability for such payroll costs. 
  

	 	4.	Right to Extend Term. As of the date of this First Amendment, the first paragraph of Section 39(a) of the Lease is hereby deleted in its entirety and replaced with the following and Tenant
shall have no other right to extend the Term of the Lease except as set forth in Section 39; 

 “(a) Extension
Rights. Tenant shall have one right (the “Extension Right”) to extend the term of this Lease for three (3) years (the “Extension Term”) on the same terms and conditions as this Lease (other than Base Rent)
by giving Landlord written notice of its election to exercise the Extension Right at least nine (9) months prior, and no earlier than twelve (12) months prior, to the expiration of the Base Term of the Lease. 

Upon the commencement of the Extension Term, Base Rent shall be payable at the Market Rate (as defined below). Base Rent shall thereafter be
adjusted on each annual anniversary of the commencement of the Extension Term by a percentage as determined at the time the Market Rate is determined. As used herein, “Market Rate” shall mean the then market rental rate as
determined by Landlord for combined laboratory and office space in Cambridge, Massachusetts of comparable age, quality, level of finish and proximity to amenities and public transit. In addition, Landlord may impose a reasonably determined market
rent for the parking rights provided hereunder.” 
  

	 	5.	Brokers. Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, “Broker”) in connection with the transaction reflected
in this First Amendment and that no Broker brought about this transaction, other than Colliers International (whose commission shall be paid by Landlord pursuant to a separate agreement). Landlord and Tenant each hereby agree to indemnify and hold
the other harmless from and against any claims by any Broker, other than Colliers International, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this First
Amendment. 

  
  

			
	

	 	 Copyright © 2005, Alexandria Real Estate Equities, Inc. ALL

RIGHTS RESERVED. Confidential and Proprietary – Do Not

Copy or Distribute. Alexandria and the Alexandria Logo are

registered trademarks of Alexandria Real Estate Equities, Inc.

  

									
		 		 	2	 		 	

	 	6.	Miscellaneous. 

 a. This First Amendment is the entire agreement between the
parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. This First Amendment may be amended only by an agreement in writing, signed by the parties hereto. 

b. This First Amendment is binding upon and shall inure to the benefit of the parties hereto, and their respective successors and assigns. 

c. This First Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which when taken
together shall constitute one and the same instrument. The signature page of any counterpart may be detached therefrom without impairing the legal effect of the signature(s) thereon provided such signature page is attached to any other counterpart
identical thereto except having additional signature pages executed by other parties to this First Amendment attached thereto. 
 d. Except
as amended and/or modified by this First Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this First Amendment. In the event of any conflict
between the provisions of this First Amendment and the provisions of the Lease, the provisions of this First Amendment shall prevail. Whether or not specifically amended by this First Amendment, all of the terms and provisions of the Lease are
hereby amended to the extent necessary to give effect to the purpose and intent of this First Amendment. 
 [Signatures are on the next
page.] 

  
  

			
	

	 	 Copyright © 2005, Alexandria Real Estate Equities, Inc. ALL

RIGHTS RESERVED. Confidential and Proprietary – Do Not

Copy or Distribute. Alexandria and the Alexandria Logo are

registered trademarks of Alexandria Real Estate Equities, Inc.

  

									
		 		 	3	 		 	

 IN WITNESS WHEREOF, the parties hereto have executed this First Amendment as of the day
and year first above written. 
  

			
	TENANT:
	
	IDERA PHARMACEUTICALS, INC.,
	a Delaware corporation
		
	By:	 	 /s/ Louis J. Arcudi, III

		 	February 21, 2014
		
	Its:	 	Louis J. Arcudi, III
		 	Chief Financial Officer
		 	Idera Pharmaceuticals Inc.
	
	LANDLORD:
	
	ARE-MA REGION NO. 23, LLC,
	a Delaware limited liability company
		
	By:	 	ALEXANDRIA REAL ESTATE EQUITIES, L.P., a Delaware limited partnership, managing member
		
	By:	 	ARE-QRS CORP.,
		 	a Maryland corporation,
		 	general partner
		
	By:	 	 /s/ Eric S. Johnson

	Its:	 	Eric S. Johnson
		 	Vice President
		 	Real Estate Legal Affairs

  
  

			
	

	 	 Copyright © 2005, Alexandria Real Estate Equities, Inc. ALL

RIGHTS RESERVED. Confidential and Proprietary – Do Not

Copy or Distribute. Alexandria and the Alexandria Logo are

registered trademarks of Alexandria Real Estate Equities, Inc.

  

									
		 		 	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]